Plain-English translation of NCT07308847 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Sphere-360 catheter paired with the Affera mapping and ablation system, a new tool designed to treat paroxysmal atrial fibrillation (PAF)—a condition where your heart suddenly starts beating irregularly for short periods. The procedure, called pulmonary vein isolation, uses the device to carefully target and treat the heart tissue causing the irregular rhythm. Researchers want to see if this treatment is safe and effective at stopping these episodes.
Many patients with paroxysmal atrial fibrillation continue to have troubling symptoms despite current treatments. This trial exists to evaluate whether the new treatment offers a better or safer way to help patients control their irregular heartbeats.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo a catheter ablation procedure using the new Sphere-360 device and Affera system. During the procedure, doctors thread a thin catheter through your blood vessels to your heart to map and treat the areas causing irregular rhythm. You would need to be on blood-thinning medication for at least 3 weeks before the procedure and would attend follow-up visits to monitor your recovery and assess how well the treatment worked.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States